Puretech Health - PRTC STOCK NEWS

Vedanta Biosciences, a clinical-stage company based in Cambridge, Massachusetts, is pioneering new oral therapies derived from defined bacterial consortia. CEO Bernat Olle, Ph.D., will participate in a panel at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022. The panel, titled 'Great Debate - Is the Term “Microbiome” Drug Development Passé?', is set for 3:15 PM ET, followed by Olle's presentation at 4:30 PM ET. The company focuses on treating high-risk C. difficile infections, inflammatory bowel diseases, and more.

PureTech Health announced significant findings from a study on AKL-T01 (EndeavorRx) for children with ADHD. The research demonstrated enhanced brain activity related to attention, as evidenced by increased midline frontal theta (MFT) activity in EEG readings. This activity correlated with improved behavioral measures, as parents reported a decrease in inattention symptoms. The study, published in PLOS ONE, reinforces EndeavorRx's efficacy in targeting cognitive functions, paving the way for ongoing clinical development and commercialization.

PureTech Health (Nasdaq: PRTC) announces that its Founded Entity, Akili Interactive, has filed a Form S-4 registration with the SEC concerning its proposed business combination with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). This filing includes a preliminary proxy statement/prospectus with critical details about Akili. The merger is anticipated to conclude by mid-2022, leading to Akili being listed on Nasdaq under the new ticker symbol “AKLI.” The registration statement is available for review on the SEC's website.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, announced that Bharatt Chowrira, Ph.D., J.D., and Julie Krop, M.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 10:00 am EST. The presentation can be accessed via webcast on their investors’ page. With a robust pipeline of 25 therapeutics, PureTech focuses on developing differentiated medicines for severe diseases, including inflammatory and neurological conditions.

Gelesis Holdings (NYSE: GLS) has launched the "Who Said?" marketing campaign for Plenity, aiming to challenge cultural norms around weight loss. This campaign targets the 70% of Americans struggling with excess weight and promotes a new approach to weight management without deprivation. Plenity is FDA-cleared and uses a biomimetic method to enhance satiety, resulting in an average weight loss of 22 pounds in clinical trials. Gelesis anticipates $58 million in revenue for 2022 during its first full year post-launch.

Follica, a biotechnology company, presented survey data on androgenetic alopecia (AGA) treatment at the 2022 Winter Clinical Dermatology Conference. The survey of 303 male participants aged 18-49 revealed significant dissatisfaction with existing AGA treatments, with 64% noting a negative impact on their lives. An overwhelming 74% expressed interest in a novel investigational in-office treatment. The findings underscore the unmet needs in AGA therapies and the potential market for Follica's innovative approach, expected to advance through upcoming clinical trials.

PureTech Health's Founded Entity, Gelesis, has completed a business combination with Capstar Special Purpose Acquisition Corp. Gelesis will begin trading on the New York Stock Exchange under the ticker symbol 'GLS' on January 14, 2022, after securing approximately $105 million in gross proceeds. These funds will primarily support the national launch of Plenity, an FDA-cleared weight management product. With 71 million Americans having gained weight during the pandemic, Gelesis aims to address the rising demand for effective weight management solutions.

PureTech Health plc, a clinical-stage biotherapeutics company, announced that Daphne Zohar, the CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30am EST. The company focuses on developing innovative medicines for severe diseases, including inflammatory and neuropsychological disorders. PureTech has a robust pipeline of 25 therapeutic candidates, with two receiving FDA and European marketing approvals. A webcast of the presentation will be available on their investor site.